The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10353 capsules", a Category 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansen Technology Co. Ltd., subsidiaries of the company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of depression and other diseases. The specific indication will be determined after the completion of clinical research.